Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 52-Week High at $25.36

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY)’s stock price hit a new 52-week high during trading on Thursday . The company traded as high as $25.36 and last traded at $24.20, with a volume of 295992 shares traded. The stock had previously closed at $23.53.

Chugai Pharmaceutical Stock Up 3.4 %

The business’s fifty day moving average is $19.82 and its 200 day moving average is $18.39. The firm has a market capitalization of $82.18 billion, a price-to-earnings ratio of 36.74 and a beta of 0.87.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Thursday, July 25th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a net margin of 32.68% and a return on equity of 21.45%. The business had revenue of $2.03 billion for the quarter. Equities research analysts expect that Chugai Pharmaceutical Co., Ltd. will post 0.78 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.